WO2006136871A1 - Utilisation d'extraits de pollen pour traiter des infections, des neoplasmes et pour equilibrer la reponse immunitaire - Google Patents

Utilisation d'extraits de pollen pour traiter des infections, des neoplasmes et pour equilibrer la reponse immunitaire Download PDF

Info

Publication number
WO2006136871A1
WO2006136871A1 PCT/IB2005/001750 IB2005001750W WO2006136871A1 WO 2006136871 A1 WO2006136871 A1 WO 2006136871A1 IB 2005001750 W IB2005001750 W IB 2005001750W WO 2006136871 A1 WO2006136871 A1 WO 2006136871A1
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
immune response
pollen
neoplasms
balance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2005/001750
Other languages
English (en)
Inventor
Chiara De Gregorio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Codex V Srl
Original Assignee
Codex V Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Codex V Srl filed Critical Codex V Srl
Priority to PCT/IB2005/001750 priority Critical patent/WO2006136871A1/fr
Publication of WO2006136871A1 publication Critical patent/WO2006136871A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines

Definitions

  • This invention relates to the use of pollen extracts to prepare medicinal products designed to activate/rebalance the immune response.
  • Pollen has a complex chemical composition and comprises proteins and aminoacids, carbohydrates, lipids, mineral salts and trace elements, vitamins, hormones, enzymes, growth factors, water-extractable antibiotic substances and nucleic acids.
  • Pollen extracts which are available on the market from a number of sources, are mainly used in the cosmetic field, as active ingredients of formulations for dry, normal and greasy skins due to their nutrient properties.
  • Pollen extracts obtained by extraction of pollens of various origins with aqueous, hydroalcoholic, oily or glycolic solvents, are also used as tonics and as adjuvants in the treatment of states of mental and physical fatigue, depression and asthenia.
  • EP 1077725 filed by the Applicant, discloses that the association of pollen extract with vegetable oil unsaponifiables, applied topically, is suitable to treat a number of conditions, mainly of dermatological and circulatory interest, with an inflammatory, immune, degenerative or proliferative base.
  • EP 1313492-6 disclose the use of pollen extracts, possibly associated with royal jelly and Vitamin E, to treat dysphoria associated with normal hormonal variations in women of childbearing, peri- and post-menopausal age.
  • Chinese patents CN1391911 and WO99/11279 disclose the use of pollen extracts for the treatment of benign prostatic hyperplasia and prostatitis.
  • pollen extracts suitably formulated for oral, topical, transdermal, intramuscular or intravenous administration, has led to improvements in infectious diseases and neoplastic disorders, and often to a cure.
  • the pollen extracts which can be used according to the invention may be of different types and origins, such as hydroalcoholic, aqueous, oily or glycol extracts.
  • the extracts will be administered by oral, parenteral or topical administration, depending on the site affected by the disorder to be treated, at doses which can vary within a wide range in view of the substantial absence of toxicity of the extract. Broadly speaking, 10 mg to 500 mg a day can be given in one or more administrations by the oral or parenteral route, while a formulation of 0.1 to 10% in weight of extract can be used for topical or transdermal administration.
  • the extracts will be suitably formulated in transdermal systems, capsules, tablets, solutions for oral or parenteral use, suspensions, creams, gels or the like, in association with conventional excipients or vehicles, and possibly with other active ingredients with a complementary or otherwise useful activity.
  • the transdermal formulations may contain suitable absorption promoters in conventional use.
  • disorders that respond to the treatment according to the invention include:
  • Oncological disorders such as tumours in situ, affecting the limbs and lymph node stations or at an advanced stage.
  • non-Hodgkin's lymphoma even at an advanced stage of the disease, such as the 3rd or 4th stage according to the TNM classification
  • the treatment of these disorders requires from 4-5 days to several months' application of the gel or transdermal system to which the invention relates.
  • the treatment may also be accompanied by the administration of pollen extract, especially oral administration.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention a pour objet l'utilisation d'extrait de pollen pour préparer des produits médicinaux pour le traitement d'infections systémiques et de troubles néoplasiques qui peuvent être localisés ou à un stade avancé.
PCT/IB2005/001750 2005-06-21 2005-06-21 Utilisation d'extraits de pollen pour traiter des infections, des neoplasmes et pour equilibrer la reponse immunitaire Ceased WO2006136871A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IB2005/001750 WO2006136871A1 (fr) 2005-06-21 2005-06-21 Utilisation d'extraits de pollen pour traiter des infections, des neoplasmes et pour equilibrer la reponse immunitaire

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2005/001750 WO2006136871A1 (fr) 2005-06-21 2005-06-21 Utilisation d'extraits de pollen pour traiter des infections, des neoplasmes et pour equilibrer la reponse immunitaire

Publications (1)

Publication Number Publication Date
WO2006136871A1 true WO2006136871A1 (fr) 2006-12-28

Family

ID=36084216

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/001750 Ceased WO2006136871A1 (fr) 2005-06-21 2005-06-21 Utilisation d'extraits de pollen pour traiter des infections, des neoplasmes et pour equilibrer la reponse immunitaire

Country Status (1)

Country Link
WO (1) WO2006136871A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952399A (en) * 1985-09-20 1990-08-28 Cernitin Sa Pharmaceutical composition which inhibits the growth of a tumor
RU2090198C1 (ru) * 1991-03-12 1997-09-20 Иван Иванович Уваров Способ получения биологически активных веществ, обладающих противогрибковой активностью
US5712377A (en) * 1995-06-30 1998-01-27 Cerbios-Pharma Sa Glycosides isolated from pollen, their sugar-free decomposition products and derivatives thereof
WO2002032442A1 (fr) * 2000-10-20 2002-04-25 Biolee Co., Ltd. Preparation externe pour la peau contenant du pollen de pin ou un extrait de celui-ci
EP1364943A1 (fr) * 2001-02-02 2003-11-26 Ajinomoto Co., Inc. Nouveaux derives de cystine et inhibiteurs de l'activation des facteurs inflammatoires
US20040147459A1 (en) * 2002-10-23 2004-07-29 Joseph Oneal Method and composition for maintaining urinary tract health in the face of infections

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952399A (en) * 1985-09-20 1990-08-28 Cernitin Sa Pharmaceutical composition which inhibits the growth of a tumor
RU2090198C1 (ru) * 1991-03-12 1997-09-20 Иван Иванович Уваров Способ получения биологически активных веществ, обладающих противогрибковой активностью
US5712377A (en) * 1995-06-30 1998-01-27 Cerbios-Pharma Sa Glycosides isolated from pollen, their sugar-free decomposition products and derivatives thereof
WO2002032442A1 (fr) * 2000-10-20 2002-04-25 Biolee Co., Ltd. Preparation externe pour la peau contenant du pollen de pin ou un extrait de celui-ci
EP1364943A1 (fr) * 2001-02-02 2003-11-26 Ajinomoto Co., Inc. Nouveaux derives de cystine et inhibiteurs de l'activation des facteurs inflammatoires
US20040147459A1 (en) * 2002-10-23 2004-07-29 Joseph Oneal Method and composition for maintaining urinary tract health in the face of infections

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199823, Derwent World Patents Index; Class B04, AN 1998-259253, XP002375085 *
WÓJCICKI J ET AL: "The effect of Cernitins on galactosamine-induced hepatic injury in rat.", ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS. 1985, vol. 33, no. 2, 1985, pages 361 - 370, XP008062497, ISSN: 0004-069X *

Similar Documents

Publication Publication Date Title
US20020110604A1 (en) Composition exhibiting synergistic antioxidant activity
US8158161B2 (en) Methods and pharmaceutical compositions useful for treating psoriasis
EP2155222B1 (fr) Extrait de trigonella foenum-graecum
EP2953628B1 (fr) Creme a base de basidiomycetes pour le traitement des maladies cutanees
JPH11501284A (ja) アポトーシスを阻害する組成物、その組成物の精製方法およびその使用
WO2019223699A1 (fr) Polysaccharide biologique pour la prévention et le traitement de l'acné et de la dermatite liée aux stéroïdes et son utilisation
US20250188461A1 (en) Methods of treating osmidrosis
EP1001759B1 (fr) Inhibition virale au moyen d'alcools, alcanes, acides gras et amides a chaine longue
Ruzhentsova et al. Efficacy and safety of favipiravir in a complex therapy of mild to moderate COVID-19
RU2535053C2 (ru) Фармацевтическая композиция, содержащая лизин и ферменты: лизоцим, дезоксирибонуклеазу и/или пероксидазу для наружного лечения и профилактики инфекций, вызванных вирусом герпеса типа 1,2 и бактериальных осложнений, вызываемых герпетической инфекцией
Gedik et al. The antimicrobial effect of various formulations obtained from Fomes fomentarius against hospital isolates
WO2006136871A1 (fr) Utilisation d'extraits de pollen pour traiter des infections, des neoplasmes et pour equilibrer la reponse immunitaire
Quiles et al. Coenzyme Q differentially modulates phospholipid hydroperoxide glutathione peroxidase gene expression and free radicals production in malignant and non‐malignant prostate cells
TW200816984A (en) Naphthalenedione compounds
US20140107223A1 (en) Topical ubiquinol supplement skin care compositions
US20170273938A1 (en) Use of flavonoids in manufacturing compositions for wound healing
Dreno Roferon‐A (interferon alpha 2a) combined with Tigason (etretinate) for treatment of cutaneous T cell lymphomas
EP1441768A1 (fr) Chlorambucil parenteral utilise dans le traitement de maladies malignes et auto-immunes, et procedes d'utilisation associes
JPH10298099A (ja) 細胞賦活組成物
JPH06199694A (ja) 血圧安定化治療剤
RU2535052C1 (ru) Фармацевтическая композиция, содержащая производные лизина, пролина и тритерпеновой кислоты для лечения и профилактики вирусных инфекций, вызываемых рнк и днк-содержащими вирусами, такими как: грипп, герпес, опоясывающий лишай, папиллома человека, аденоновирусы, а также бактериальных инфекций, вызываемых грам-положительными и грам-отрицательными микроорганизмами
JP2001261567A (ja) 皮膚外用剤
US20120082742A1 (en) Method and compositions for treating cutaneous verrucae
JPH0827015A (ja) ブドウ色素を含有する飼料
RU2519133C1 (ru) Мазь, содержащая инкапсулированную тритерпеновую кислоту или ее производные

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05772299

Country of ref document: EP

Kind code of ref document: A1